The University of Queensland in Australia was awarded a $520,011 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from August 1, 2022 to July 31, 2025 on a novel mediator of cholangiocarcinoma that has potential as a diagnostic and treatment target. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...
The Department of the Army Medical Command awarded a $1,126,472 project grant under the Military Medical Research and Development (CFDA 12.420) program to The University of Auckland in New Zealand. The purpose of the grant is to identify the earliest druggable targets for Parkinson's disease. The award has a performance period from September 1, 2024 to August 31, 2027. As a prominent international research institution, The University of Auckland has established a strong track record of...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $968,717 to the University of Melbourne in Australia to conduct research aimed at solving a major complication of Parkinson's disease - debilitating constipation - through novel pharmacology. The research project will run from April 2025 to April 2028, targeting innovative solutions to address this significant health challenge for military service members and...
The Council Of The Queensland Institute Of Medical Research (QIMR Berghofer Medical Research Institute) received a $439,692.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The funding supports research to use genetics to identify new endometrial cancer therapeutics. This work involves genomic analysis, variant classification, risk assessment tools, and preclinical drug validation. QIMR Berghofer partners with...
The U.S. Department of the Army Medical Command awarded a $494,774 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Aarhus Universitet, a Danish educational institution, to develop nonmotor biomarkers to diagnose Parkinson's disease subtypes early on. The award, which runs from December 15, 2024 to December 14, 2026, will support advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader...
The University of Queensland in Australia was awarded a $744,744 USD project grant from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project titled "Understanding the Role of Immature Myeloid Cells in Early Melanoma Establishment" from September 30, 2022 to September 29, 2025. Through this funding, researchers at The University of Queensland will investigate the role of immature myeloid...
This federal Project Grant award of $1,021,409.00 from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program will support research at the University of Illinois to investigate the underlying neurobiology of non-motor symptoms in Parkinson's disease. The research aims to elucidate the role of serotonin system plasticity in the development of these disabling non-motor complications, which can include cognitive, psychiatric, and...
This federal Project Grant award of $1,117,328.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Queensland in Australia to develop proteomic biomarkers for amyotrophic lateral sclerosis (ALS) disease prognosis and progression monitoring. The award has a performance period from April 1, 2025 to March 31, 2027 and aims to transform healthcare for military service members, veterans, and the broader public...
This federal Project Grant award of $1,156,726.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of Queensland (UQ) in Australia. The objective of the research project is to predict early-stage melanoma at high risk of recurrence through multiomics profiling. The award has a performance period from September 1, 2025 to August 31, 2028. UQ, a leading Australian research university, has an extensive...
The University of Queensland in Australia was awarded a $1,488,596 Project Grant from the Department of the Army Medical Command to support melanoma research from September 2022 through September 2025. The grant is funded through the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health care through innovative biomedical research solutions for battlefield medicine and other health issues. Under this award, The University of Queensland...